Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions

European Journal of Nuclear Medicine

Volumn 28, Issue 6, 2001, Pages 730-735

  Zhao, Songji ^a   Kuge, Yuji ^a   Tsukamoto, Eriko ^a   Mochizuki, Takafumi ^b   Kato, Takashi ^a   Hikosaka, Kenji ^a   Hosokawa, Masuo ^a   Kohanawa, Masashi ^a   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nikko Memorial Hospital   (Japan)

Author keywords

FDG PET; Glucose; Inflammation; Insulin; Tumour

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; TURPENTINE OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; HEPATOMA CELL; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; LIVER CELL CARCINOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; STAPHYLOCOCCUS AUREUS;

ANIMALS; BLOOD GLUCOSE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOPLASM TRANSPLANTATION; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; STAPHYLOCOCCAL INFECTIONS; TISSUE DISTRIBUTION;

EID: 0035020365     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590100517     Document Type: Article

References (34)

1. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-675.
2. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancre atic tumors with positron emission tomography and F-18 flu orodeoxyglucose: comparison with CT and US. Radiology 1995; 195:345-352.
3. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diag nosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31:1927-1932.
4. Vitola JV, Delbeke D, Sandier MP, et al. Positron emission to mography to stage suspected metastatic colorectal carcinomato the liver. Am J Surg 1996; 171:21-26.
5. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary andmetastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765-770.
6. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correla tive lymph node mapping and sampling. Radiology 1997;202:441-446.
7. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35:1965-1969.
8. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B,Cody R. Metabolic monitoring of breast cancer chemohormo notherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101-2111.
9. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI,Orringer MB. Staging of mediastinal non-small cell lung can cer with FDG PET, CT, and fusion images: preliminary pro spective evaluation. Radiology 1994; 191:371-377.
10. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levelsof glucose transport and transporter messenger RNA are in duced by ras or src oncogenes. Science 1987; 235:1492-1495.
11. 18F]-fiuorodeoxy glucose uptake in abdominal abscesses: a PET study. J Com put Assist Tomogr 1989; 13:829-831.
12. 18F] FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990; 14:486-487.
13. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglu cose in sarcoidosis, J Nucl Med 1994; 35:1647-1649.
14. Ichiya Y, Kuwabara Y, Sasaki M, et al. FDG-PET in infectiouslesions: the detection and assessment of lesion activity. Ann Nucl Med 1996; 10:185-191.
15. Hanson MW, Glantz MJ, Hoffman JM, et al. FDG-PET in theselection of brain lesions for biopsy. J Comput Assist Tomogr 1991; 15:796-801.
16. Meyer MA, Frey KA, Schwaiger M. Discordance betweenF-18 fluorodeoxyglucose uptake and contrast enhancement in a brain abscess. Clin Nucl Med 1993; 18:682-684.
17. Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR,Wahl RL. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med 1998; 25:1238-1243.
18. 125I-HSA. Eur J Nucl Med 1999; 26:333-341.
19. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High ac cumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995; 36:1301-1306.
20. Minn H, Nuutila P, Lindholm P, et al. In vivo effects of insulinon tumor and skeletal muscle glucose metabolism in patientswith lymphoma. Cancer 1994; 73:1490-1498.
21. Torizuka T, Fisher SJ, Wahl RL. Insulin-induced hypoglyce mia decreases uptake of 2-[F-18]fluoro-2-deoxy-D-glucose in to experimental mammary carcinoma. Radiology 1997; 203:169-172.
22. Torizuka T, Fisher SJ, Brown RS, Wahl RL. Effect of insulinon uptake of FDG by experimental mammary carcinoma in diabetic rats. Radiology 1998; 208:499-504.
23. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-de oxy-D-glucose in rodents with mammary carcinoma. Radiology 1992; 183:643-647.
24. Langen KJ, Braun U, Rota Kops E, et al. The influenceof plasma glucose levels on fluorine-18-fluorodeoxyglucoseuptake in bronchial carcinomas. J Nucl Med 1993; 34:355-359.
25. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsa Lainen U, Joensuu H. Influence of the blood glucose concen tration on FDG uptake in cancer: a PET study. J Nucl Med 1993; 34:1-6.
26. Kuramitsu Y, Nishibe M, Ohiro Y, et al. A new synthetic lipidA analog, ONO-4007, stimulates the production of tumor necrosis factor-alpha in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells. Anticancer Drugs 1997;8:500-508.
27. 18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol 1990; 17:273-279.
28. Ishizu K, Nishizawa S, Yonekura Y, et al. Effects of hypergly cemia on FDG uptake in human brain and glioma. J Nucl Med 1994; 35:1104-1109.
29. Herholz K, Wienhard K, Heiss WD. Validity of PET studies inbrain tumors. Cerebrovasc Brain Metab Rev 1990; 2:240-265.
30. James DE. Targeting of the insulin-regulatable glucose trans porter (GLUT-4). Biochem Soc Trans 1994; 22:668-670.
31. Virkamaki A, Puhakainen I, Koivisto VA, Vuorinen-MarkkolaH, Yki-Jarvinen H. Mechanisms of hepatic and peripheral in sulin resistance during acute infections in humans. J Clin Endocrinol Metab 1992; 74:673-679.
32. Garvey WT, Maianu L, Zhu JH, Brechtel-Hook G, Wallace P,Baron AD. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as acause of human insulin resistance. J Clin Invest 1998;101:2377-2386.
33. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammationand normal tissue in the head and neck. Eur J Nucl Med 1999;26:1345-1348.
34. Mochizuki T, Tsukamoto E, Kuge Y, et al. Difference of FDGuptake and GLUT expression between inflammation and malignant tumor [abstract]. J Nucl Med 2000; 41:257P.